LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced total enrollment is complete in ARISE (Acid Lipase Replacement Investigating Safety and Efficacy), a global Phase 3 trial with sebelipase alfa in children and adults with lysosomal acid lipase deficiency (LAL Deficiency). Enrollment exceeded the original target of 50 patients with 66 randomized as of December 31, 2013. As previously announced, the company expects to report top-line results from the ARISE trial during the second half of 2014.
Help employers find you! Check out all the jobs and post your resume.
